

Antibody-mediated neuroimmunological diseases, such as myasthenia gravis, neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) frequently affect women during their reproductive years. Yet, counselling around family planning and pregnancy for people with these conditions has long been characterised by uncertainty and therapeutic hesitation. The systematic exclusion of women of childbearing age, including those who are pregnant, from clinical trials is rooted in legitimate safety concerns following historical tragedies, such as thalidomide use in the 1950s and 1960s.
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet